Sanofi Unveils Promising Phase III Results for Rilzabrutinib
Sanofi has announced positive Phase III results for rilzabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor in development for immune thrombocytopenia (ITP). The French pharmaceutical company tested the treatment in adults with ITP and observed a significant improvement in platelet counts. Patients on rilzabrutinib showed a median time to first platelet response of 36 days, … Read more